These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 26496934)
1. Why the drug development pipeline is not delivering better medicines. Naci H; Carter AW; Mossialos E BMJ; 2015 Oct; 351():h5542. PubMed ID: 26496934 [No Abstract] [Full Text] [Related]
2. An insider's perspective: defense of the pharmaceutical industry's marketing practices. Johar K Albany Law Rev; 2012-2013; 76(1):299-334. PubMed ID: 23577377 [No Abstract] [Full Text] [Related]
3. The High Cost of Insulin in the United States: An Urgent Call to Action. Rajkumar SV Mayo Clin Proc; 2020 Jan; 95(1):22-28. PubMed ID: 31902423 [No Abstract] [Full Text] [Related]
4. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada. Openshaw MS Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902 [TBL] [Abstract][Full Text] [Related]
5. America's other drug problem: how the drug industry distorts medicine and politics. Relman AS; Angell M New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803 [No Abstract] [Full Text] [Related]
6. Risky business. Ment Health Today; 2005 May; ():12-3. PubMed ID: 15938578 [No Abstract] [Full Text] [Related]
7. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase]. Kock M; Thomsen MK Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820 [TBL] [Abstract][Full Text] [Related]
9. Who pays what in drug development. Love J Nature; 1999 Jan; 397(6716):202. PubMed ID: 9930689 [No Abstract] [Full Text] [Related]
10. Marketing decision support systems for strategy building. Rao SK Mark Health Serv; 2000; 20(2):14-8. PubMed ID: 11183424 [TBL] [Abstract][Full Text] [Related]
11. Drug development for neglected diseases - the trouble with FDA review vouchers. Kesselheim AS N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367 [No Abstract] [Full Text] [Related]
12. The marketplace can't give us the drug safety data we need. Avorn J MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636 [No Abstract] [Full Text] [Related]
14. The future of off-label marketing regulations in the post-Sorrell era. Iraggi J Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338 [No Abstract] [Full Text] [Related]
15. The European Medicines Agency is still too close to industry. Garattini S BMJ; 2016 May; 353():i2412. PubMed ID: 27154140 [No Abstract] [Full Text] [Related]
16. Pharmaceuticals and medical devices: FDA oversight. ; Berry MD; White RS Issue Brief Health Policy Track Serv; 2014 Dec; ():1-96. PubMed ID: 25775703 [No Abstract] [Full Text] [Related]
17. Walking the drug regulatory tightrope. Dove A Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571 [No Abstract] [Full Text] [Related]
18. [Discouraging about drug therapy?]. Reseland S Tidsskr Nor Laegeforen; 2003 Jun; 123(13-14):1910-1. PubMed ID: 12830286 [No Abstract] [Full Text] [Related]
19. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law. Dinh TQ Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027 [No Abstract] [Full Text] [Related]
20. [The long path (s) of placing medicines on the market]. Duguet C Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():13-17. PubMed ID: 30943154 [No Abstract] [Full Text] [Related] [Next] [New Search]